The purpose of this legislation, known as the FDA Modernization Act 3.0, is to update and improve the regulations surrounding nonclinical testing methods used in the development of drugs and medical products. It aims to replace outdated references to animal testing with broader terms that encompass various nonclinical testing approaches, reflecting advancements in science and technology. Key provisions of the Act require the Secretary of Health and Human Services, through the Commissioner of Food and Drugs, to publish an interim final rule within one year of the law's enactment.